QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 theriva-biologics-secures-4m-via-immediate-exercise-of-736m-warrants-at-054share-offers-investors-1472m-new-warrants-at-same-price

Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing t...

 theriva-biologics-to-present-vcn-12-and-vcn-01-preclinical-data-at-esgct-highlighting-novel-antitumor-mechanism-and-intracranial-feasibility-for-brain-tumors

- Preclinical data for VCN-12, the next candidate from Theriva's VCN-X discovery program, highlight a novel mechanism of ac...

 stock-market-today-nasdaq-sp-500-futures-gain-on-3rd-day-of-government-shutdownrumble-riggeti-kodiak-in-focus-updated

U.S. stock futures advanced on Friday following Thursday's record advances. Futures of major benchmark indices were higher.

 rumble-xcel-brands-and-3-stocks-to-watch-heading-into-friday

US stock futures up, Actelis Networks, XCel Brands, Rumble Inc. up after hours. Theriva Biologics to cut workforce, Open Text t...

 theriva-biologics-cuts-32-of-workforce-in-restructuring-to-focus-on-cancer-drug-development-and-regulatory-strategy-expects-will-extend-its-cash-runway-into-q2-of-2026

Item 2.05 Costs Associated with Exit or Disposal Activities. On September 28, 2025, the Board of Directors of Theriva Biologics...

 theriva-biologics-has-received-a-notice-of-allowance-for-a-us-patent-titled-alkaline-phosphatase--formulations-for-the-treatment-of-microbiome-related-diseases

https://patentcenter.uspto.gov/applications/18744950/ifw/docs

 theriva-biologics-q2-eps-193-misses-108-estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1...

 theriva-biologics-to-present-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-asco-2025-announces-investigator-meeting-to-review-topline-data-from-virage-phase-2b-trial-of-vcn-01-in-metastatic-pancreatic-cancer

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION